[go: up one dir, main page]

HUP0003250A1 - Káliumcsatorna gátló hatású indánszármazékok és az ezeket tartalmazó gyógyszerkészítmények - Google Patents

Káliumcsatorna gátló hatású indánszármazékok és az ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0003250A1
HUP0003250A1 HU0003250A HUP0003250A HUP0003250A1 HU P0003250 A1 HUP0003250 A1 HU P0003250A1 HU 0003250 A HU0003250 A HU 0003250A HU P0003250 A HUP0003250 A HU P0003250A HU P0003250 A1 HUP0003250 A1 HU P0003250A1
Authority
HU
Hungary
Prior art keywords
optionally substituted
hydrogen atom
formula
general formula
potassium channel
Prior art date
Application number
HU0003250A
Other languages
English (en)
Inventor
George Amato
Serge Beaudoin
Neil Alexander Castle
Michael Gross
Sean Patrick Hollinshead
Philip Floyd Hughes
Grant Mcnaughton-Smith
Jose Serafin Mendoza
Joseph Wendell Wilson
Original Assignee
Eli Lilly And Co.
Icagen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Co., Icagen, Inc. filed Critical Eli Lilly And Co.
Publication of HUP0003250A1 publication Critical patent/HUP0003250A1/hu
Publication of HUP0003250A3 publication Critical patent/HUP0003250A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Heads (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Amplifiers (AREA)
  • Optical Communication System (AREA)
  • Separation By Low-Temperature Treatments (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

A találmány tárgyát a káliumcsatorna gátló hatású (I), (II), (III) és(IV) általános képletű vegyületek, valamint ezeket tartalmazógyógyászati készítmények képezik. A találmány szerinti vegyületekeredményesen alkalmazhatók szívaritmia, valamint a sejtburjánzássalkapcsolatos rendellenességek kezelésére. A találmány szerinti (I)általános képletű vegyületekben a szubsztituensek jelentése akövetkező: R1 jelentése hidrogénatom, alkil-, adott esetbenszubsztituált aril-, adott esetben szubsztituált heteroaril-, adottesetben szubsztituált heterociklusos vagy adott esetben szubsztituáltkarbocikloalkilcsoport; R2 jelentése alkil-, adott esetbenszubsztituált aril-, adott esetben szubsztituált heteroaril-, adottesetben szubsztituált heterociklusos vagy adott esetben szubsztituáltkarbocikloalkilcsoport; R3 jelentése hidrogénatom vagy metilcsoport;R4 jelentése hidrogénatom vagy metilcsoport; X1 jelentése C=O, C=Svagy SO2; X2 jelentése C=O vagy SO2; Y1 jelentése O, (CH2)p, CH2O,HC=CH vagy NH, ahol a képletben p értéke 0, 1 vagy 2; Y2 jelentése O,(CH2)q, HC=CH vagy NH; ahol a képletben q értéke 0 vagy 1; Z jelentéseH, OR5 vagy NR6R7; azzal a megkötéssel, hogy amennyiben Z jelentésehidrogénatom, úgy X1 és X2 egyidejűleg nem jelenthet C=O-t, miközbenY1 jelentése (CH2)p, ahol p értéke 0, miközben Y2 jelentése (CH2)q,ahol q értéke 0, és miközben R1 és R2 jelentése egyaránt metilcsoport.A (IV) általános képletben a R1 jelentése adott esetben szubsztituáltaril- vagy adott esetben szubsztituált heteroarilcsoport; R2 jelentéseadott esetben szubsztituált aril- vagy adott esetben szubsztituáltheteroarilcsoport és Y1 jelentése O, (CH2)p, CH2O, HC=CH vagy NH, ahola képletben p értéke 0, 1 vagy 2; és Z jelentése előnyösenhidrogénatom vagy OR5. A (III) általános képletben a szubsztituensek jelentése az (II)általános képlet szerintinél szűkebb körű. Ó
HU0003250A 1996-07-26 1997-07-23 Potassium channel inhibitor indane derivatives and pharmaceutical compositions containing the same HUP0003250A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2254796P 1996-07-26 1996-07-26
US08/893,160 US6083986A (en) 1996-07-26 1997-07-15 Potassium channel inhibitors
PCT/US1997/012559 WO1998004521A1 (en) 1996-07-26 1997-07-23 Potassium channel inhibitors

Publications (2)

Publication Number Publication Date
HUP0003250A1 true HUP0003250A1 (hu) 2002-01-28
HUP0003250A3 HUP0003250A3 (en) 2002-02-28

Family

ID=26696048

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0003250A HUP0003250A3 (en) 1996-07-26 1997-07-23 Potassium channel inhibitor indane derivatives and pharmaceutical compositions containing the same

Country Status (13)

Country Link
US (1) US6083986A (hu)
EP (1) EP0923543B1 (hu)
JP (1) JP2002513385A (hu)
KR (1) KR20000029605A (hu)
AT (1) ATE250571T1 (hu)
AU (1) AU734711B2 (hu)
BR (1) BR9710587A (hu)
CA (1) CA2261814A1 (hu)
DE (1) DE69725153T2 (hu)
HK (1) HK1020334A1 (hu)
HU (1) HUP0003250A3 (hu)
IL (1) IL128205A (hu)
WO (1) WO1998004521A1 (hu)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8591898A (en) * 1997-07-22 1999-02-16 Eli Lilly And Company Pharmaceutical compounds
US6333337B1 (en) 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
US6197798B1 (en) 1998-07-21 2001-03-06 Novartis Ag Amino-benzocycloalkane derivatives
CO5090829A1 (es) * 1998-07-21 2001-10-30 Novartis Ag Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b.
JP2002523451A (ja) 1998-09-01 2002-07-30 ブリストル−マイヤーズ スクイブ カンパニー カリウムチャネル抑制剤および方法
US6632836B1 (en) 1998-10-30 2003-10-14 Merck & Co., Inc. Carbocyclic potassium channel inhibitors
US6303637B1 (en) 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
US6194458B1 (en) 1998-10-30 2001-02-27 Merck & Co., Inc. Benzamide potassium channel inhibitors
DE19929076A1 (de) * 1999-06-25 2000-12-28 Aventis Pharma Gmbh Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
EP1214293A1 (en) * 1999-09-08 2002-06-19 Guilford Pharmaceuticals Inc. Non-peptidic cyclophilin binding compounds and their use
US6531495B1 (en) 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
JP2003518101A (ja) 1999-12-21 2003-06-03 アイカゲン インコーポレイテッド カリウムチャネル阻害剤
PT1259484E (pt) 2000-01-18 2005-09-30 Novartis Ag Carboxamidas uteis como inibidores de proteina de transferencia de triglicerido microsomal e de secrecao de apolipoproteina b
US6566380B2 (en) * 2000-07-25 2003-05-20 Icagen, Inc. Potassium channel inhibitors
US6620849B2 (en) 2000-07-26 2003-09-16 Icafen, Inc. Potassium channel inhibitors
AU2002214522A1 (en) * 2000-11-17 2002-05-27 Karolinska Innovations Ab Nucleotide and polypeptide sequences of kcna7, a mammalian voltage-gated potassium channel protein, and use thereof
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) * 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10061876A1 (de) 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US6849634B2 (en) 2000-12-21 2005-02-01 Icagen Potassium channel inhibitors
US6656971B2 (en) 2001-01-25 2003-12-02 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
WO2002087306A2 (en) * 2001-05-01 2002-11-07 Senomyx, Inc. High throughput cell-based assay for monitoring sodium channel activity and discovery of salty taste modulating compounds
WO2005014848A2 (en) 2003-07-10 2005-02-17 Senomyx, Inc. IMPROVED ELECTROPHYSIOLOGICAL ASSAYS USING OOCYTES THAT EXPRESS HUMAN ENaC AND THE USE OF PHENAMIL TO IMPROVE THE EFFECT OF ENaC ENHANCERS IN ASSAYS USING MEMBRANE POTENTIAL REPORTING DYES
US10078087B2 (en) 2001-05-01 2018-09-18 Senomyx, Inc. Assays and enhancers of the human delta ENaC sodium channel
AU2002314132A1 (en) * 2001-05-31 2002-12-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw New heterotetrameric potassium channels and uses thereof
DE10128331A1 (de) 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
KR100820511B1 (ko) * 2004-04-01 2008-04-11 파마시아 앤드 업존 캄파니 엘엘씨 결정성 피라졸 유도체
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
US8565898B2 (en) * 2005-04-28 2013-10-22 Medtronic, Inc. Rate control during AF using cellular intervention to modulate AV node
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
US8633160B2 (en) * 2005-12-30 2014-01-21 Nono Inc. Small molecule inhibitors of PDZ interactions
WO2008066900A1 (en) * 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
WO2009006611A1 (en) * 2007-07-03 2009-01-08 Arbor Vita Corporation Small molecule inhibitors of pdz interactions
EP2527328A1 (en) 2008-04-01 2012-11-28 Abbott GmbH & Co. KG Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
GB0815781D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
EP2417101B1 (en) * 2009-04-09 2013-10-23 Merck Sharp & Dohme B.V. Indane derivatives
GB0909672D0 (en) * 2009-06-04 2009-07-22 Xention Discovery Ltd Compounds
GB0909671D0 (en) * 2009-06-04 2009-07-22 Xention Discovery Ltd Compounds
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) * 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
ES2615738T3 (es) 2011-05-13 2017-06-08 Array Biopharma, Inc. Compuestos de pirrolidinil urea, pirrolidinil tiourea y pirrolidinil guanidina como inhibidores de trkA quinasa
NO3175985T3 (hu) 2011-07-01 2018-04-28
CA2844275A1 (en) 2011-08-05 2013-02-14 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
JP2014533675A (ja) 2011-11-18 2014-12-15 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー Ｎ置換アミノベンゾシクロヘプテン、アミノテトラリン、アミノインダンおよびフェナルキルアミン誘導体、これらを含有する医薬組成物、および治療におけるこれらの使用
NZ627942A (en) 2012-01-27 2016-03-31 Gilead Sciences Inc Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013130808A1 (en) 2012-02-29 2013-09-06 D.E. Shaw Research, Llc Methods for screening voltage gated proteins
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
ES2664331T3 (es) 2012-11-13 2018-04-19 Array Biopharma, Inc. Compuestos de N-pirrolidinilo, N'-pirazolilurea, tiourea, guanidina y cianoguanidina como inhibidores de la cinasa Trka
WO2014078325A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078328A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078454A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
WO2014078417A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078331A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2015055770A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
MX2016004934A (es) 2013-10-17 2016-12-20 Abbvie Deutschland Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
ES2746530T3 (es) 2014-05-15 2020-03-06 Array Biopharma Inc 1-((3S,4R)-4-(3-fluorofenil)-1-(2-metoxietil)pirrolidín-3-il)-3-(4-metil-3-(2-metilpirimidín-5-il)-1-fenil-1H-pirazol-5- il)urea como un inhibidor de TrkA cinasa

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB536939A (en) * 1939-08-24 1941-06-03 Eastman Kodak Co Improvements in and relating to photographic colour development
IL62973A0 (en) * 1980-06-02 1981-07-31 Basf Ag Aralkylphenylureas,their manufacture and their use as herbicides
JPS60199862A (ja) * 1984-03-23 1985-10-09 Otsuka Pharmaceut Co Ltd インダン誘導体
GB8707123D0 (en) * 1987-03-25 1987-04-29 Pfizer Ltd Antiarrhythmic agents
US5006512A (en) * 1987-10-02 1991-04-09 Tsuyoshi Ohnishi Therapeutic usages of inhibitors for a potassium efflux channel
IL88314A (en) * 1987-11-18 1994-05-30 Tanabe Seiyaku Co History of sulfonylamino indane, their preparation and pharmaceutical preparations containing them
PT89205B (pt) * 1987-12-14 1993-06-30 Beecham Group Plc Processo para a preparacao de derivados de indano
US5242947A (en) * 1988-02-10 1993-09-07 New York University Use of polyamines as ionic-channel regulating agents
DE3818245A1 (de) * 1988-05-28 1989-12-07 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit kaliumkanal-modulatoren sowie deren verwendung in arzneimitteln
US5215985A (en) * 1990-07-20 1993-06-01 E. R. Squibb & Sons, Inc. Method for treating ischemic insult to neurons employing an ATP-sensitive potassium channel blocker
EP0472053B1 (en) * 1990-08-20 1998-06-17 Eisai Co., Ltd. Sulfonamide derivatives
US5401848A (en) * 1990-11-26 1995-03-28 E. R. Squibb & Sons, Inc. Indane and quinoline derivatives
US5310932A (en) * 1991-04-15 1994-05-10 E. R. Squibb & Sons, Inc. Chromanyl substituted indole potassium channel openers
US5234947A (en) * 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
US5356775A (en) * 1992-07-29 1994-10-18 Brigham & Women's Hospital Primary structure for functional expression from complementary DNA of a mammalian ATP-sensitive potassium channel
US5328830A (en) * 1992-09-08 1994-07-12 Miles Inc. Potassium channel modulators
US5374643A (en) * 1992-09-11 1994-12-20 E. R. Squibb & Sons, Inc. Aryl urea (thiourea) and cyanoguanidine derivatives
US5453421A (en) * 1992-09-11 1995-09-26 E. R. Squibb & Sons, Inc. Aryl and heterocyclic substituted propenamide derivatives
DE4302051A1 (de) * 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
GB9309716D0 (en) * 1993-05-12 1993-06-23 Zeneca Ltd Heterocyclic derivatives
US5401758A (en) * 1993-10-07 1995-03-28 Bristol-Myers Squibb Company Pyridinyl cyanoguanidine compounds
JP4782252B2 (ja) * 1994-01-10 2011-09-28 テバ ファーマシューティカル インダストリーズ リミテッド １−アミノインダン及びこれらの組成物
FR2717805B1 (fr) * 1994-03-28 1996-05-10 Rhone Poulenc Rorer Sa Dérivés de 5H-indeno[1,2-b]pyrazine-2,3-dione, leur préparation et les médicaments les contenant .
US5615460A (en) * 1994-06-06 1997-04-01 The Procter & Gamble Company Female component for refastenable fastening device having regions of differential extensibility
ZA96211B (en) * 1995-01-12 1996-07-26 Teva Pharma Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
AU5772396A (en) * 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
US6429317B1 (en) * 1996-01-22 2002-08-06 Eli Lilly And Company Indane derivatives for antipsychotic compositions

Also Published As

Publication number Publication date
JP2002513385A (ja) 2002-05-08
ATE250571T1 (de) 2003-10-15
WO1998004521A1 (en) 1998-02-05
AU3803597A (en) 1998-02-20
HUP0003250A3 (en) 2002-02-28
US6083986A (en) 2000-07-04
KR20000029605A (ko) 2000-05-25
HK1020334A1 (en) 2000-04-14
CA2261814A1 (en) 1998-02-05
IL128205A0 (en) 1999-11-30
IL128205A (en) 2003-09-17
BR9710587A (pt) 2000-10-31
DE69725153D1 (de) 2003-10-30
EP0923543B1 (en) 2003-09-24
AU734711B2 (en) 2001-06-21
EP0923543A1 (en) 1999-06-23
DE69725153T2 (de) 2004-06-09

Similar Documents

Publication Publication Date Title
HUP0003250A1 (hu) Káliumcsatorna gátló hatású indánszármazékok és az ezeket tartalmazó gyógyszerkészítmények
WO1998004521B1 (en) Potassium channel inhibitors
ATE33838T1 (de) Thiazolidinderivate, ihre herstellung und diese enthaltende zusammensetzungen.
HUP0103283A2 (hu) Proteázokat gátló pirazinonszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint a vegyületek alkalmazása
WO1999033858A3 (en) Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use
ATE231837T1 (de) Hydroxamsäure- und carbonsäurederivate mit mmp und tnf hemmender wirkung
HUP0004529A2 (hu) VLA-4 által mediált leukocita adhéziót gátló szulfonilezett dipeptid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint alkalmazásuk
MXPA02003199A (es) Derivados de sulfonamida farmaceuticamente activos.
YU13396A (sh) N-(3-benzofuranil) urea derivati, postupci za njihovo dobijanje, kompozicije koje ih sadrže i njihova upotreba u lekovima
GB1384031A (en) N-substituted dihydropyridine compounds their production and their medicinal use
HUP9802290A2 (hu) Pirrolszármazékok és az azokat tartalmazó gyógyászati kompozíciók
BG100069A (bg) Амидинови производни,съдържащи хетероциклични групи,получаване и приложението им
HUP0001164A2 (hu) PF1022-ciklodepszipeptid-származékok
MY100115A (en) Nitrogen containing heterocyclic compounds, and their production and use.
DE3575554D1 (de) Aminosaeurederivate mit antitumoraktivitaet sowie diese derivate enthaltende zusammensetzungen.
EA200300044A1 (ru) Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции
HUP0104620A2 (hu) 2-Fenil-pirán-4-on-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ES8101884A1 (es) Procedimiento de obtencion de composiciones cosmeticas
ES2032501T3 (es) Un procedimiento de preparacion de derivados de urileno-2,4,6-triamino-3-oxido.
TR199700354A2 (xx) Karbohidrat t�revleri.
DK379281A (da) Azolylalkyl-derivater fremgangsmaade til deres fremstilling og deres anvendelse som fungicider
IE832680L (en) Nitrosourea derivatives.
ATE47135T1 (de) Antikonvulsive mittel.
DE3687385D1 (de) 2-substituierte-1,4-dihydropyridine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
FI870460A0 (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 5-substituerade oktahydroindolizinderivat och vid foerfarandet anvaendbara mellanprodukter.

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished